{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T09:52:42Z","timestamp":1767952362238,"version":"3.49.0"},"reference-count":81,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The research of Prof. Dr. Thomas C. Merigan has spanned almost half a century. It started in 1963 with his interest in interferon (i). He then identified pyran copolymer as a synthetic polyanionic inducer of interferon (ii), and thereafter thiophosphate-substituted polyribonucleotides, i.e., poly r(s\u00afA-s\u00afU) (iii). He recognized the potential of interferon as a therapeutic agent for virus infections (iv), varicella-zoster virus (VZV) being the first case in point (v). His interest then shifted to the treatment of herpes virus [herpes simplex virus (HSV) and cytomegalovirus (CMV)] infections (vi) and hepatitis B virus (HBV) infections (vii), to end up with human immunodeficiency virus (HIV) infections (viii, ix, x). T.C. Merigan\u2019s pioneering work on the treatment of so many pivotal virus infections deserves further in-depth clinical evaluation.<\/jats:p>","DOI":"10.3390\/molecules31010025","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T11:43:31Z","timestamp":1766403811000},"page":"25","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pioneering Role of T.C. Merigan in the Treatment of Various Virus Infections"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-8890","authenticated-orcid":false,"given":"Erik","family":"De Clercq","sequence":"first","affiliation":[{"name":"Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, B-3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1126\/science.145.3634.811.b","article-title":"Purified interferons: Physical properties and species specificity","volume":"145","author":"Merigan","year":"1964","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1056\/NEJM196507222730405","article-title":"Circulating interferon after measles vaccination","volume":"273","author":"Petralli","year":"1965","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0140-6736(65)90755-5","article-title":"Action of endogenous interferon against vaccinia infection in children","volume":"2","author":"Petralli","year":"1965","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM196704202761608","article-title":"Interferons of mice and men","volume":"276","author":"Merigan","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/214416a0","article-title":"Induction of circulating interferon by synthetic anionic polymers of known composition","volume":"214","author":"Merigan","year":"1967","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1056\/NEJM196712142772403","article-title":"Interferon induction in man by a synthetic polyanion of defined composition","volume":"277","author":"Merigan","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1128\/jvi.2.9.878-885.1968","article-title":"Antiviral activity of polyacrylic and polymethacrylic acids. I. Mode of action in vitro","volume":"2","author":"Billiau","year":"1968","journal-title":"J. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1128\/jvi.2.9.886-893.1968","article-title":"Antiviral activity of polyacrylic and polymethacrylic acids. II. Mode of action in vivo","volume":"2","author":"Billiau","year":"1968","journal-title":"J. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0042-6822(68)90215-8","article-title":"Interferon-stimulating and in vivo antiviral effects of various synthetic anionic polymers","volume":"35","author":"Merigan","year":"1968","journal-title":"Virology"},{"key":"ref_10","unstructured":"De Clercq, E. (1971). Mechanism of the Antiviral Activity of Synthetic Polyanions. [Ph.D. Thesis, KU Leuven]."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/2221148a0","article-title":"Requirement of a stable secondary structure for the antiviral activity of polynucleotides","volume":"222","author":"Merigan","year":"1969","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1126\/science.165.3898.1137","article-title":"Interferon induction increased through chemical modification of a synthetic polyribonucleotide","volume":"165","author":"Eckstein","year":"1969","journal-title":"Science"},{"key":"ref_13","first-page":"187","article-title":"Interferon induction by and ribonuclease sensitivity of thiophosphate-substituted polyribonucleotides","volume":"9","author":"Eckstein","year":"1969","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"899","DOI":"10.4049\/jimmunol.103.5.899","article-title":"An active interferon inducer obtained from Hemophilus influenzae type B","volume":"103","author":"Merigan","year":"1969","journal-title":"J. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","article-title":"Virus interference. I. The interferon","volume":"147","author":"Isaacs","year":"1957","journal-title":"Proc. R. Soc. Lond. B Biol. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev.me.21.020170.000313","article-title":"Current concepts of interferon and interferon induction","volume":"21","author":"Merigan","year":"1970","journal-title":"Annu. Rev. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/226364a0","article-title":"Increase in antiviral activity of polynucleotides by thermal activation","volume":"226","author":"Wells","year":"1970","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/archinte.1970.00310070096009","article-title":"Induction of interferon by nonviral agents","volume":"126","author":"Merigan","year":"1970","journal-title":"Arch. Intern. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1085\/jgp.56.1.57","article-title":"Nonviral interferon inducers","volume":"56","author":"Merigan","year":"1970","journal-title":"J. Gen. Physiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1172\/JCI106374","article-title":"The role of interferon in the protective effect of a synthetic double-stranded polyribonucleotide against intranasal vesicular stomatitis virus challenge in mice","volume":"49","author":"Nuwer","year":"1970","journal-title":"J. Clin. Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/228219a0","article-title":"Interferon stimulated by double stranded RNA","volume":"228","author":"Merigan","year":"1970","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0022-2836(71)90086-6","article-title":"Thermal activation of the antiviral activity of synthetic double-stranded polyribonucleotides","volume":"56","author":"Wells","year":"1971","journal-title":"J. Mol. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1126\/science.169.3951.1213","article-title":"Tilorone hydrochloride: An orally active antiviral agent","volume":"169","author":"Krueger","year":"1970","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.169.3951.1214","article-title":"Tilorone hydrochloride: Mode of action","volume":"169","author":"Mayer","year":"1970","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/infdis\/123.2.190","article-title":"Bis-DEAE-fluorenone: Mechanism of antiviral protection and stimulation of interferon production in the mouse","volume":"123","author":"Merigan","year":"1971","journal-title":"J. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0042-6822(72)90276-0","article-title":"Studies on the antiviral activity and cell interaction of synthetic double-stranded polyribo- and polydeoxyribonucleotides","volume":"47","author":"Wells","year":"1972","journal-title":"Virology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1073\/pnas.58.3.1004","article-title":"Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes","volume":"58","author":"Field","year":"1967","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1128\/AAC.3.2.198","article-title":"Studies on the toxicity and antiviral activity of various polynucleotides","volume":"3","author":"Black","year":"1973","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(73)90714-9","article-title":"Inhibition of respiratory virus infection by locally applied interferon","volume":"1","author":"Merigan","year":"1973","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/infdis\/158.5.934","article-title":"Topical interferon for treating condyloma acuminata in women","volume":"158","author":"Keay","year":"1988","journal-title":"J. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJM197402072900608","article-title":"Host defenses against viral disease","volume":"290","author":"Merigan","year":"1974","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1056\/NEJM197901043000113","article-title":"Human interferon as a therapeutic agent","volume":"300","author":"Merigan","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1056\/NEJM198306233082510","article-title":"Human interferon as a therapeutic agent\u2014current status","volume":"308","author":"Merigan","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJM198306233082501","article-title":"Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal-transplant recipients","volume":"308","author":"Hirsch","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1056\/NEJM197310252891701","article-title":"Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial","volume":"289","author":"Stevens","year":"1973","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/infdis\/130.1.56","article-title":"Administration of human leukocyte interferon in herpes zoster. I. Safety, circulating, antiviral activity, and host responses to infection","volume":"130","author":"Jordan","year":"1974","journal-title":"J. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJM197605272942212","article-title":"Editorial: Efficacy of adenine arabinoside in herpes zoster","volume":"294","author":"Merigan","year":"1976","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJM197605272942201","article-title":"Adenine arabinoside therapy of herpes zoster in the immunosuppressed. NIAID collaborative antiviral study","volume":"294","author":"Whitley","year":"1976","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1128\/AAC.13.4.605","article-title":"Human leukocyte interferon in the treatment of varicella in children with cancer: A preliminary controlled trial","volume":"13","author":"Arvin","year":"1978","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJM197805042981801","article-title":"Human leukocyte interferon for the treatment of herpes zoster in patients with cancer","volume":"298","author":"Merigan","year":"1978","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1056\/NEJM198204013061301","article-title":"Human leukocyte interferon for the treatment of varicella in children with cancer","volume":"306","author":"Arvin","year":"1982","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/S0140-6736(81)92570-8","article-title":"Controlled clinical trial of intravenous acyclovir in heart-transplant patients with mucocutaneous herpes simplex infections","volume":"1","author":"Chou","year":"1981","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"655","DOI":"10.7326\/0003-4819-93-5-655","article-title":"Cytomegalovirus retinitis in immunosuppressed hosts. I. Natural history and effects of treatment with adenine arabinoside","volume":"93","author":"Pollard","year":"1980","journal-title":"Ann. Intern. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1128\/AAC.25.1.25","article-title":"Alpha-interferon administration in cytomegalovirus retinitis","volume":"25","author":"Chou","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/infdis\/156.6.1016","article-title":"Ganciclovir treatment of cytomegalovirus infections in iatrogenically immunocompromised patients","volume":"156","author":"Keay","year":"1987","journal-title":"J. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S563","DOI":"10.1093\/clinids\/10.Supplement_3.S563","article-title":"Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients","volume":"10","author":"Keay","year":"1988","journal-title":"Rev. Infect. Dis."},{"key":"ref_47","first-page":"122","article-title":"Treatment of cytomegalovirus infection in the AIDS patient","volume":"23","author":"Merigan","year":"1991","journal-title":"Transplant. Proc."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM199204303261803","article-title":"A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation","volume":"326","author":"Merigan","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJM197609022951001","article-title":"Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis","volume":"295","author":"Greenberg","year":"1976","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1001\/jama.1978.03280430064020","article-title":"Effect of vidarabine on chronic hepatitis B virus infection","volume":"239","author":"Pollard","year":"1978","journal-title":"JAMA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/hep.1840010306","article-title":"Antiviral treatment of chronic hepatitis B virus infection: Improvement in liver disease with interferon and adenine arabinoside","volume":"1","author":"Scullard","year":"1981","journal-title":"Hepatology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/143.6.772","article-title":"Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside","volume":"143","author":"Scullard","year":"1981","journal-title":"J. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/hep.1840020107","article-title":"Antiviral treatment of chronic hepatitis B virus infection: Infectious virus cannot be detected in patient serum after permanent responses to treatment","volume":"2","author":"Scullard","year":"1982","journal-title":"Hepatology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1128\/AAC.21.1.93","article-title":"Antiviral treatment of chronic hepatitis B virus infection: Pharmacokinetics and side effects of interferon and adenine arabinoside alone and in combination","volume":"21","author":"Sacks","year":"1982","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","first-page":"481","article-title":"Therapeutic approaches to chronic hepatitis B","volume":"7","author":"Smith","year":"1982","journal-title":"Prog. Liver Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1001\/jama.1982.03320410043029","article-title":"Vidarabine monophosphate and human leukocyte interferon in chronic hepatitis B infection","volume":"247","author":"Smith","year":"1982","journal-title":"JAMA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1128\/AAC.29.1.122","article-title":"Preliminary trial of recombinant fibroblast interferon in chronic hepatitis B virus infection","volume":"29","author":"Eisenberg","year":"1986","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/infdis\/157.5.1076","article-title":"Recombinant fibroblast interferon and immune interferon for treating chronic hepatitis B virus infection: \tPatients\u2019 tolerance and the effect on viral markers","volume":"157","author":"Bissett","year":"1988","journal-title":"J. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJM198411153112009","article-title":"What are we going to do about AIDS and HTLV-III\/LAV infection?","volume":"311","author":"Merigan","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/infdis\/159.3.390","article-title":"A personal view of efforts in treatment of human immunodeficiency virus infection in 1988","volume":"159","author":"Merigan","year":"1989","journal-title":"J. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-112-4-247","article-title":"Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial","volume":"112","author":"Schooley","year":"1990","journal-title":"Ann. Intern. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"11s","DOI":"10.1016\/0002-9343(90)90415-A","article-title":"Safety and tolerance of dideoxycytidine as a single agent. Results of early-phase studies in patients with acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex. Study Group of the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases","volume":"88","author":"Merigan","year":"1990","journal-title":"Am. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"20s","DOI":"10.1016\/0002-9343(90)90417-C","article-title":"Alternating and intermittent regimens of zidovudine (3\u2032-azido-3\u2032-deoxythymidine) and dideoxycytidine (2\u2032,3\u2032-dideoxycytidine) in the treatment of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex","volume":"88","author":"Skowron","year":"1990","journal-title":"Am. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"8s","DOI":"10.1016\/0002-9343(91)90405-M","article-title":"Treatment of AIDS with combinations of antiretroviral agents","volume":"90","author":"Merigan","year":"1991","journal-title":"Am. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"321","DOI":"10.7326\/0003-4819-118-5-199303010-00001","article-title":"Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex","volume":"118","author":"Skowron","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-121-4-199408150-00005","article-title":"Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy","volume":"121","author":"Kozal","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/infdis\/172.1.70","article-title":"Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy","volume":"172","author":"Shafer","year":"1995","journal-title":"J. Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJM199604183341602","article-title":"Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine","volume":"334","author":"Collier","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.7326\/0003-4819-124-12-199606150-00003","article-title":"The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients","volume":"124","author":"Schapiro","year":"1996","journal-title":"Ann. Intern. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJM199610103351501","article-title":"A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team","volume":"335","author":"Hammer","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"906","DOI":"10.7326\/0003-4819-128-11-199806010-00008","article-title":"Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients","volume":"128","author":"Shafer","year":"1998","journal-title":"Ann. Intern. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1086\/314541","article-title":"Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229","volume":"179","author":"Schapiro","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1172\/JCI4948","article-title":"A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors","volume":"102","author":"Winters","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1086\/314751","article-title":"Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons","volume":"179","author":"Lawrence","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1128\/AAC.45.8.2276-2279.2001","article-title":"Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nuleoside analogs","volume":"45","author":"Winters","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/135965350000500101","article-title":"Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. The Terry Beirn Community Programs for Clinical Research on AIDS","volume":"5","author":"Winters","year":"2000","journal-title":"Antivir. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1089\/08892220050140900","article-title":"Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells","volume":"16","author":"Gray","year":"2000","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa030264","article-title":"Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection","volume":"349","author":"Robbins","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1056\/NEJMoa030265","article-title":"Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection","volume":"349","author":"Shafer","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1086\/497610","article-title":"Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and\/or Nelfinavir: An Adult Aids Clinical Trials Group Study","volume":"192","author":"Haas","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nm.1932","article-title":"Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells","volume":"15","author":"Mitsuyasu","year":"2009","journal-title":"Nat. Med."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/1\/25\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T08:09:15Z","timestamp":1767946155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/1\/25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["molecules31010025"],"URL":"https:\/\/doi.org\/10.3390\/molecules31010025","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]}}}